Open access · CC-BY
via OpenAlex
Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD
Lindsay T. Fourman, James M. Billingsley, George Agyapong, Shannan J. Ho Sui, Meghan N. Feldpausch, Julia Purdy, Isabel Zheng, Chelsea S. Pan, Kathleen E. Corey, Martin Torriani, David Erwin Kleiner, Colleen M. Hadigan, Takara Leah Stanley, Raymond T. Chung, Steven Kyle Grinspoon
JCI Insight · 2020 · ▲ 25 citations
Abstract
Nonalcoholic fatty liver disease (NAFLD) is a common comorbidity among people living with HIV that has a more aggressive course than NAFLD among the general population. In a recent randomized placebo-controlled trial, we demonstrated that the growth hormone-releasing hormone analog tesamorelin reduced liver fat and prevented fibrosis progression in HIV-associated NAFLD over 1 year. As such, tesamorelin is the first strategy that has shown to be effective against NAFLD among the population with HIV. The current study leveraged paired liver biopsy specimens from this trial to identify hepatic gene pathways that are differentially modulated by tesamorelin versus placebo. Using gene set enrichment analysis, we found that tesamorelin increased hepatic expression of hallmark gene sets involved in oxidative phosphorylation and decreased hepatic expression of gene sets contributing to inflammation, tissue repair, and cell division. Tesamorelin also reciprocally up- and downregulated curated gene sets associated with favorable and poor hepatocellular carcinoma prognosis, respectively. Notably, among tesamorelin-treated participants, these changes in hepatic expression correlated with improved fibrosis-related gene score. Our findings inform our knowledge of the biology of pulsatile growth hormone action and provide a mechanistic basis for the observed clinical effects of tesamorelin on the liver.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1172/jci.insight.140134
- Canonical
- link ↗
- Fetched
- 2026-10-15 MST
Cite this
APA
Fourman, L.T., Billingsley, J.M., Agyapong, G., Sui, S.J.H., Feldpausch, M.N., Purdy, J., Zheng, I., Pan, C.S., Corey, K.E., Torriani, M., Kleiner, D.E., Hadigan, C.M., Stanley, T.L., Chung, R.T., & Grinspoon, S.K. (2020). Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD. <em>JCI Insight</em>. https://doi.org/10.1172/jci.insight.140134
Vancouver
Fourman LT, Billingsley JM, Agyapong G, Sui SJH, Feldpausch MN, Purdy J, et al. Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD. JCI Insight. 2020. doi:10.1172/jci.insight.140134.
BibTeX
@article{lindsay2020Effect,
title = {Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD},
author = {Lindsay T. Fourman and James M. Billingsley and George Agyapong and Shannan J. Ho Sui and Meghan N. Feldpausch and Julia Purdy and Isabel Zheng and Chelsea S. Pan and Kathleen E. Corey and Martin Torriani and David Erwin Kleiner and Colleen M. Hadigan and Takara Leah Stanley and Raymond T. Chung and Steven Kyle Grinspoon},
journal = {JCI Insight},
year = {2020},
doi = {10.1172/jci.insight.140134},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Biomedicines 2022
Open access · CC-BY
The Role of Gut–Liver Axis in Gut Microbiome Dysbiosis Associated NAFLD and NAFLD-HCC
Scientific Reports 2011
Open access · CC-BY
The metabolic footprint of aging in mice
AIDS 2020
Preprint · CC-BY
Liver steatosis and nonalcoholic fatty liver disease with fibrosis are predictors of frailty in people living with HIV
bioRxiv (Cold Spring Harbor Laboratory) 2021
Preprint · OA
Necroptosis contributes to chronic inflammation and fibrosis in aging liver
Aging Cell 2021
Open access · CC-BY
Necroptosis contributes to chronic inflammation and fibrosis in aging liver
Clinical and Molecular Hepatology 2022
Open access · CC-BY